



Back to Infomemo Search

DATE: JUNE 5, 2014

SUBJECT: INOVIO PHARMACEUTICALS, INC. – REVERSE SPLIT

OPTION SYMBOL: INO NEW SYMBOL: INO1

DATE: 6/6/14

Inovio Pharmaceuticals, Inc. (INO) has announced a 1-for-4 reverse stock split. As a result of the reverse stock split, each INO Common Share will be converted into the right to receive .25 (New) Inovio Pharmaceuticals, Inc. (INO) Common Shares. The reverse stock split will become effective at the market open on June 6, 2014.

CONTRACT ADJUSTMENT

Effective Date: June 6, 2014

Option Symbol: INO changes to INO1

Contract

Multiplier: 1

Strike Divisor: 1

New Multiplier: 100 (e.g., for premium or strike dollar extensions 1.00 will

equal \$100)

New Deliverable

Per Contract: 25 (New) Inovio Pharmaceuticals, Inc. (INO) Common Shares

CUSIP: INO (New): 45773H201

PRICING

The underlying price for INO1 will be determined as follows:

INO1 = .25 (INO)

DISCLAIMER

This Information Memo provides an unofficial summary of the terms of corporate events affecting listed options or futures prepared for the convenience of market participants. OCC accepts no responsibility for the accuracy or completeness of the summary, particularly for information which may be relevant to investment decisions. Option or futures investors should independently ascertain and evaluate all information concerning this corporate event(s).

The determination to adjust options and the nature of any adjustment is made by a panel of The OCC Securities Committee pursuant to OCC By-Laws, Article VI, Sections 11 and 11A. The adjustment panel is comprised of representatives from OCC and each exchange which trades the affected option. The determination to adjust futures and the nature of any adjustment is made by OCC pursuant to OCC By-Laws, Article XII, Sections 3, 25, or 25A, as applicable. For both options and futures, each adjustment decision is made on a case by case basis. Adjustment decisions are based on information available at the time and are subject to change as additional information becomes available or if there are material changes to the terms of the corporate event(s) occasioning the adjustment.

For questions regarding this memo, call 1-888-678-4667 or email investorservices@theocc.com.